Csenge Advisory Group Purchases 166 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Csenge Advisory Group raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 21.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 943 shares of the company’s stock after purchasing an additional 166 shares during the period. Csenge Advisory Group’s holdings in IDEXX Laboratories were worth $509,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of IDXX. Valley National Advisers Inc. boosted its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $26,000. DSM Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $33,000. Venturi Wealth Management LLC raised its position in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares in the last quarter. Finally, Private Wealth Management Group LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $34,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded up $5.65 during trading hours on Thursday, hitting $489.04. The company’s stock had a trading volume of 166,753 shares, compared to its average volume of 465,650. The company’s 50 day simple moving average is $499.93 and its two-hundred day simple moving average is $523.00. The company has a market cap of $40.39 billion, a P/E ratio of 46.79, a price-to-earnings-growth ratio of 3.95 and a beta of 1.32. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IDXX shares. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. Barclays lowered their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Finally, Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $586.63.

View Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Stories

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.